Skip to main content
Premium Trial:

Request an Annual Quote

TGen, Active Motif, Beckman Coulter, Thermo Fisher

Premium
TGen Licenses Active Motif’s Data-Mining Platform
 
Active Motif, a research tools and bioinformatics company, today said that Translational Genomics has licensed its data-mining software.
 
TGen will use the AKS2 software in genomic-profiling projects such as high-throughput siRNA screening, Active Motif said.
 
Jeff Kiefer, head of TGen’s Knowledge Mining Lab, said the software will be used in the company’s pharmacogenomic programs to help integrate information from research literature.
 
Financial terms of the agreement were not released.
 

 
Beckman Coulter Posts 8.6-Percent Rise in Q4 Revenue as Profit Widens 250 Percent
 
Beckman Coulter this week said fourth-quarter revenues increased 8.6 percent as R&D spending receded 2.7 percent and profit jumped 250 percent.
 
Total receipts for the three months ended Dec. 31, 2006, increased to $712 million from $655.5 million year over year.
 
Product-related revenue increased 8.1 percent to $104 million while service-related revenue was up 8.7 percent to $608 million.
 
R&D spending decreased slightly to $57.6 million from $59.2 million in the previous fourth quarter.
 
The company said profit increased to $62.3 million from $17.8 million in the year-ago period.
 
The company attributed the increase to smaller operating expenses. Specifically, in the fourth quarter in 2005 the company paid $32.9 million more in restructuring costs, had a $10.7 million “asset impairment” charge, and spent $11.4 million more in selling and administrative costs.
 
Beckman said it had around $75.2 million in cash and equivalents as of Dec. 31, 2006.
 
The company said it expects 2007 revenue to grow between 7 percent and 9 percent over 2006.
 

 
Thermo Fisher's Q4 Sales Surge 126 Percent; Profits Tumble By More Than Half
 
Thermo Fisher Scientific this week said fourth-quarter revenues increased 126 percent as R&D spending rose 36 percent and profit declined by more than half on charges related to the merger between Thermo Electron and Fisher Scientific.
 
Total receipts for the three months ended Dec. 31, 2006, increased to $1.67 billion from $741 million year over year.
 
Thermo said revenue from its Analytical Technologies segment increased 57 percent to $849 million, while receipts from the Lab Products and Services segment increased 330 percent to $861 million.
 
R&D spending increased to $52.1 million from $38.2 million in the fourth quarter of 2005.
 
The company said profit declined to $25.3 million from $56.4 million in the year-ago period. The current quarter's profits include a $125-million charge related to the Thermo-Fisher merger.
 
Thermo said it had around $667 million in cash and equivalents and $23.8 million in short-term investments as of Dec. 31, 2006.
 
Thermo Fisher Scientific was created in the fourth quarter when Thermo Electron and Fisher Scientific completed a $10.6-billion merger.

The Scan

Billions for Antivirals

The US is putting $3.2 billion toward a program to develop antivirals to treat COVID-19 in its early stages, the Wall Street Journal reports.

NFT of the Web

Tim Berners-Lee, who developed the World Wide Web, is auctioning its original source code as a non-fungible token, Reuters reports.

23andMe on the Nasdaq

23andMe's shares rose more than 20 percent following its merger with a special purpose acquisition company, as GenomeWeb has reported.

Science Papers Present GWAS of Brain Structure, System for Controlled Gene Transfer

In Science this week: genome-wide association study ties variants to white matter stricture in the brain, and more.